Detection of unamplified target genes via CRISPR–Cas9 immobilized on a graphene field-effect transistor

Reza Hajian,Sarah Balderston,Thanhtra Tran,Tara deBoer,Jessy Etienne,Mandeep Sandhu,Noreen A. Wauford,Jing-Yi Chung,Jolie Nokes,Mitre Athaiya,Jacobo Paredes,Regis Peytavi,Brett Goldsmith,Niren Murthy,Irina M. Conboy,Kiana Aran

DOI: https://doi.org/10.1038/s41551-019-0371-x

IF: 28.1

2019-03-25

Nature Biomedical Engineering

Abstract:Most methods for the detection of nucleic acids require many reagents and expensive and bulky instrumentation. Here, we report the development and testing of a graphene-based field-effect transistor that uses clustered regularly interspaced short palindromic repeats (CRISPR) technology to enable the digital detection of a target sequence within intact genomic material. Termed CRISPR–Chip, the biosensor uses the gene-targeting capacity of catalytically deactivated CRISPR-associated protein 9 (Cas9) complexed with a specific single-guide RNA and immobilized on the transistor to yield a label-free nucleic-acid-testing device whose output signal can be measured with a simple handheld reader. We used CRISPR–Chip to analyse DNA samples collected from HEK293T cell lines expressing blue fluorescent protein, and clinical samples of DNA with two distinct mutations at exons commonly deleted in individuals with Duchenne muscular dystrophy. In the presence of genomic DNA containing the target gene, CRISPR–Chip generates, within 15 min, with a sensitivity of 1.7 fM and without the need for amplification, a significant enhancement in output signal relative to samples lacking the target sequence. CRISPR–Chip expands the applications of CRISPR–Cas9 technology to the on-chip electrical detection of nucleic acids.

engineering, biomedical

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a fast, low - cost and easy - to - use genetic testing tool to overcome the limitations of traditional nucleic acid detection techniques. Specifically, the paper introduces a new method named CRISPR - Chip, which is a biosensor based on graphene field - effect transistors (gFET) and CRISPR - Cas9 technology, and can rapidly detect target gene sequences from complete genomic samples without amplification.

### Background of the Paper
Traditional nucleic acid molecular diagnostic test methods, such as PCR, although optimized in the past 30 years, still have some limitations:
- **Time - consuming**: Require multi - step reactions and are time - consuming.
- **High cost**: Require a variety of reagents and complex instruments, and are costly.
- **Complex operation**: Require trained personnel to operate.
- **Dependent on large - scale equipment**: Usually rely on large and expensive optical components for detection.

### Design and Advantages of CRISPR - Chip
CRISPR - Chip combines the gene - targeting ability of CRISPR - Cas9 and the high sensitivity of graphene field - effect transistors to achieve the following advantages:
- **Rapid detection**: Can complete the detection within 15 minutes.
- **No amplification required**: Directly detect unamplified target gene sequences, avoiding the complexity and time consumption of the amplification step.
- **High sensitivity**: The limit of detection is as low as 1.7 fM.
- **Portable**: The output signal can be read by a simple handheld device, which is convenient for on - site use.

### Experimental Verification
The paper verifies the effectiveness and specificity of CRISPR - Chip through the following several experiments:
1. **Specificity verification**: Using the PCR product of the blue fluorescent protein (BFP) gene, the specific binding ability of CRISPR - Chip to the target double - stranded DNA (dsDNA) was verified.
2. **Affinity verification**: Through the magnetic bead experiment, the affinity of the immobilized dRNP to its target sequence in the complete genomic sample was verified.
3. **Whole - genome sample detection**: In the presence of non - target genomic DNA at different concentrations, the detection ability of CRISPR - Chip to the target gene sequence was verified.
4. **Clinical application verification**: The gene mutations related to Duchenne muscular dystrophy (DMD) were detected, and the potential application value of CRISPR - Chip in clinical diagnosis was verified.

### Conclusion
The development of CRISPR - Chip provides a new solution for genetic testing, with the advantages of being fast, sensitive, portable and low - cost, and is expected to be widely used in fields such as clinical diagnosis and gene editing.